516 related articles for article (PubMed ID: 25894578)
1. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
Reck M; Mellemgaard A; von Pawel J; Gottfried M; Bondarenko I; Cheng Y; Zarogoulidis K; Luft A; Bennouna J; Barrueco J; Aboshady H; Hocke J; Kaiser R; Douillard JY;
Lung Cancer; 2015 Nov; 90(2):267-73. PubMed ID: 26415992
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis Inhibitors in NSCLC.
Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
[TBL] [Abstract][Full Text] [Related]
5. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Novello S; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Barrueco J; Gaschler-Markefski B; Griebsch I; Palmer M; Reck M;
Eur J Cancer; 2015 Feb; 51(3):317-26. PubMed ID: 25534294
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
Espinosa Bosch M; Asensi Diez R; García Agudo S; Clopes Estela A
Farm Hosp; 2016 Jun; 40(4):316-27. PubMed ID: 27571499
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
Gottfried M; Bennouna J; Bondarenko I; Douillard JY; Heigener DF; Krzakowski M; Mellemgaard A; Novello S; Orlov S; Summers Y; von Pawel J; Stöhr J; Kaiser R; Reck M
Target Oncol; 2017 Aug; 12(4):475-485. PubMed ID: 28702806
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
Popat S; Mellemgaard A; Fahrbach K; Martin A; Rizzo M; Kaiser R; Griebsch I; Reck M
Future Oncol; 2015; 11(3):409-20. PubMed ID: 25478720
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.
Popat S; Mellemgaard A; Reck M; Hastedt C; Griebsch I
Future Oncol; 2017 Jun; 13(13):1159-1171. PubMed ID: 28326832
[TBL] [Abstract][Full Text] [Related]
11. Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
Reck M; Syrigos K; Miliauskas S; Zöchbauer-Müller S; Fischer JR; Buchner H; Kitzing T; Kaiser R; Radonjic D; Kerr K
Lung Cancer; 2020 Oct; 148():159-165. PubMed ID: 32927350
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.
Reck M; Heigener D; Reinmuth N
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):579-90. PubMed ID: 25119062
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
Syrios J; Nintos G; Georgoulias V
Expert Rev Anticancer Ther; 2015; 15(8):875-84. PubMed ID: 26204906
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
Corral J; Majem M; Rodríguez-Abreu D; Carcereny E; Cortes ÁA; Llorente M; López Picazo JM; García Y; Domine M; López Criado MP
Clin Transl Oncol; 2019 Sep; 21(9):1270-1279. PubMed ID: 30771085
[TBL] [Abstract][Full Text] [Related]
16. Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
Metzenmacher M; Rizzo F; Kambartel K; Panse J; Schaufler D; Scheffler M; Azeh I; Hoiczyk M; Turki AT; Atz J; Buchner H; Hoffmann C; C Christoph D
Future Oncol; 2021 Oct; 17(30):3965-3976. PubMed ID: 34287064
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
Noonan S; Man Wong K; Jimeno A
Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
[TBL] [Abstract][Full Text] [Related]
18. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
19. Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
Grohé C; Blau W; Gleiber W; Haas S; Hammerschmidt S; Krüger S; Müller-Huesmann H; Schulze M; Wehler T; Atz J; Kaiser R
Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):459-468. PubMed ID: 35012901
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Ramalingam S; Goss G; Rosell R; Schmid-Bindert G; Zaric B; Andric Z; Bondarenko I; Komov D; Ceric T; Khuri F; Samarzija M; Felip E; Ciuleanu T; Hirsh V; Wehler T; Spicer J; Salgia R; Shapiro G; Sheldon E; Teofilovici F; Vukovic V; Fennell D
Ann Oncol; 2015 Aug; 26(8):1741-8. PubMed ID: 25997818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
